Wildix and RoboReception’s Joint AI Rollout Eliminates Missed Calls, Unlocking £9 Million in New Patient Value Across UK Healthcare
17.9.2025 15:10:00 CEST | Business Wire | Press Release
Wildix, a global leader in AI-powered business communications solutions, and RoboReception, one of the UK’s fastest-growing healthcare software providers, today announced results from an AI rollout reshaping patient access and practice economics. Since May 2025, the joint 24/7 AI receptionist has answered over 50,000 patient calls with zero missed, converting them into £9 million in new patient revenue and returning more than 2,000 hours to clinical care.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917199595/en/
Wildix and RoboReception AI Rollout Unlocks £9M in Patient Value, Handles 50,000 Calls with Zero Missed Since May 2025
Delivered with Wildix reseller Focus CX, the rollout shows how agentic voice automation relieves frontline pressure, improves patient experience and provides measurable value.
Missed calls remain one of healthcare’s hidden drains. Over a third of new patient calls go unanswered and most never call back (Dental Lifestyles Magazine; GroupDentistryNow). Those who get through face long waits and low booking rates, leaving practices with lost revenue and patients without timely care.
The Wildix–RoboReception system closes this gap by combining Wildix’s UCaaS platform powered by Wilma AI and RoboReception’s dentist-designed agentic workflows. Unlike traditional systems, it gives practices oversight: determining when AI engages, when staff intervene and how records are updated, with seamless escalation to a live agent.
Founded by practicing dentists, RoboReception was created to solve the daily front-desk problem.
“We were never taught business at dental school, only how to serve patients,” said Dr. Grant McAree, co-founder, RoboReception. “Yet every missed call meant a patient lost and pressure piling on our teams. I’ve lived that moment, drill in hand, while the phone rang unanswered. That’s why we built RoboReception, not a plug-and-play gadget, but a controllable system created by clinicians for clinicians. Together with Wildix, we’ve proven AI can work hand-in-hand with staff, giving practices back control and patients the access they deserve.”
Measured impact since rollout (May 2025, 65 practices):
- 50,000 answered calls with zero misses (vs. ~35% before AI)
- 2,000+ staff hours returned to patient care
- Nearly £700,000 in new patient value captured since launch; £2M projected in year one, £9M lifetime value
- 96% of calls fully resolved by AI, 4% escalated to staff
- 500 new patients booked monthly, booking rates rising from 18% to 70%
- Late cancellations down 75%
- 100% GDPR-compliant, encrypted, with role-based access and audit logs
“The difference here is simple: this isn’t AI running wild, it’s AI designed hand-in-hand with clinicians and live in weeks," said Dimitri Osler, chief innovation officer and co-founder, Wildix. “That’s why practices aren’t just trialing it, they’re scaling it to hundreds of sites. It shows AI can be safe, trusted and still completely game-changing for healthcare.”
The system replaces fragmented front-desk tools with a single platform that connects to patient records, CRM and scheduling to book appointments, update records and transfer calls in real time. Focus CX credited Wildix’s open APIs and engineering support for rollout in weeks, a speed described as “unheard of” in healthcare technology.
Expansion is underway to more than 500 practices worldwide, including in Ireland and Australia.
The rollout reflects Wildix’s focus on AI-enabled UCaaS that serves people first while driving growth. Wildix will showcase live demos of its AI portfolio, spanning healthcare to retail, at upcoming Partner Days. To learn more, visit www.wildix.com/partner-day/.
About Wildix
Wildix is a global UCaaS provider and the only European vendor recognized in Gartner’s Magic Quadrant for UCaaS, Worldwide. With a 100% channel-first model and deployments in more than 135 countries, Wildix serves over 1.5 million users across industries including retail, healthcare and education. Its secure, AI-driven solutions, including the flagship x-bees platform powered by Wilma AI, help businesses accelerate sales, streamline operations and adapt without friction.
About RoboReception
RoboReception is one of the UK’s fastest-growing healthcare software companies, founded by dental and healthcare professionals with in-house development teams to solve frontline challenges. Its flagship solution, RoboReception, automates call handling with workflows tailored for dental, medical, legal and financial practices, ensuring every enquiry is captured, tracked and converted. Alongside tools including ChatBot, a Reviews tool to boost Google visibility, LeadTracker and Remote Answering, RoboReception helps practices save time, grow revenue and improve patient experience.
About Focus Group
With a team of over 1,200 experts, Focus Group provides 30,000 businesses with an extensive range of the latest technology solutions across Telecoms, IT, Cyber Security, Connectivity, Mobile and Energy. Within the group, Focus CX specialises in AI, contact centre solutions, and API systems integration, delivering expertise from project inception through to go-live and ongoing support.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250917199595/en/
Contacts
Media Contact
Deliah Mathieu
VP, Global Communication, Wildix
deliah.mathieu@wildix.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 13:12:00 CEST | Press Release
Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland required for equivalent yields and logistical carbon. Digital Reef CEO Piers Slater stated "Digital Reef embrace data centre growth and environment
SLB Announces Third-Quarter 2026 Results23.10.2026 12:50:00 CEST | Press Release
SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5% 6% Income before taxes - GAAP basis $1,019 $1,018 $1,000 0% 2% Income before taxes margin - GAAP basis 10.8% 11.4% 11.2% -57 bps -42 bps Net income attributable to SLB - GAAP basis $735 $786 $739 -6% -1% Diluted EPS - GAAP basis $0.49 $0.52 $0.50 -6% -2% Adjusted EBITDA* $2,067 $1,899 $2,061 9% - Adjusted EBITDA margin* 21.9% 21.2% 23.1% 71 bps -121 bps Pretax segment operating income* $1,576 $1,404 $1,626 12% -3% Pretax segment operating margin* 16.7% 15.6% 18.2% 104 bps -153 bps Net income attributable to SLB, excluding charges & credits* $962 $833 $1,027
EZVIZ’s Smart Entry Solutions Have Consecutively Clinched the European Product Design Award and the Golden Pin Design Award, Indicating a Shift From Home Security to Living Enjoyment23.10.2026 11:58:00 CEST | Press Release
EZVIZ’s smart lock and AI-powered doorbell remained in the spotlight after IFA for bagging two world-class awards. The EP8 Ultra AI-powered video doorbell won the European Product Design Award 2026 (EPDA 2026), keeping leading in user-centric AI. Meanwhile, the DL50FVX smart lock was named the 2026 Golden Pin Design Award (GPDA) laureate for its intuitive access management and entered the finalist of the Best Design Awards. The growing prestige of EZVIZ’s smart home access management lineup marks a new chapter of providing living experiences with multi-level interaction, modern aesthetics, and emotional care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022441786/en/ Two representative models from EZVIZ's smart entry family take home prestigious awards for user-centric innovation. Founded in 2016, the EPDA aims to recognize well-thought-out products that break with tradition and improve everyday life. Continually refres
Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines23.10.2026 07:00:00 CEST | Press Release
Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the company’s Injectable Aesthetics portfolio in China – one of the world's largest and fastest-growing aesthetics markets.8,9 This approval follows successful authorizations and launches of Relfydess in more than 35 markets worldwide. Relfydess is the first and only ready-to-use liquid neuromodulator developed with PEARL Technology, designed to deliver a highly active, innovative, complex-free molecule that addresses the real needs of patients and healthcare professionals.1,2,4,5 It is optimized for simple volumetric dosing, without reconstitution, to increase ease-of-use and help ensure consistent dose/volume every time.1,10 At a time whenpatients and healthcare professionals are increasingly seeking high-performance neuromodulators that rapidly deliver long-lasting, natural-looking outcomes, Re
Mundipharma Announces Further Phase III ReSPECT Results Presented as a Late-Breaking Oral Presentation at IDWeek 202622.10.2026 19:03:00 CEST | Press Release
Today Mundipharma announced additional results from the global Phase III ReSPECT clinical trial evaluating REZZAYO®(rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT). The Phase III findings were presented today as a late-breaking oral presentation at IDWeek 2026. The presentation provides additional detail following the top line ReSPECT results announced in April 2026, including further endpoint analyses, the components contributing to fungal-free survival (FFS), pre-specified sensitivity analyses and detailed safety outcomes. The additional analyses were consistent with the previously announced topline findings. ReSPECT was a global, multicentre, randomised, double-blind Phase III study in which 402 patients were randomised to rezafungin and 200 to the standard antimicrobial regimen. As previously announced, the study met its primary endpoint, demonstrating non-inferiority
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom